tetano
Editor, Senior Moderator
Nature
. 2021 May 10.
doi: 10.1038/s41586-021-03594-0. Online ahead of print.
Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
Kevin O Saunders[SUP] 1 2 3 4 [/SUP], Esther Lee[SUP] 5 6 [/SUP], Robert Parks[SUP] 5 6 [/SUP], David R Martinez[SUP] 7 [/SUP], Dapeng Li[SUP] 5 6 [/SUP], Haiyan Chen[SUP] 5 6 [/SUP], Robert J Edwards[SUP] 5 6 [/SUP], Sophie Gobeil[SUP] 5 6 [/SUP], Maggie Barr[SUP] 5 6 [/SUP], Katayoun Mansouri[SUP] 5 6 [/SUP], S Munir Alam[SUP] 5 6 [/SUP], Laura L Sutherland[SUP] 5 6 [/SUP], Fangping Cai[SUP] 5 6 [/SUP], Aja M Sanzone[SUP] 5 6 [/SUP], Madison Berry[SUP] 5 6 [/SUP], Kartik Manne[SUP] 5 6 [/SUP], Kevin W Bock[SUP] 8 [/SUP], Mahnaz Minai[SUP] 8 [/SUP], Bianca M Nagata[SUP] 8 [/SUP], Anyway B Kapingidza[SUP] 5 6 [/SUP], Mihai Azoitei[SUP] 5 6 [/SUP], Longping V Tse[SUP] 7 [/SUP], Trevor D Scobey[SUP] 7 [/SUP], Rachel L Spreng[SUP] 5 6 [/SUP], R Wes Rountree[SUP] 5 6 [/SUP], C Todd DeMarco[SUP] 5 6 [/SUP], Thomas N Denny[SUP] 5 6 [/SUP], Christopher W Woods[SUP] 5 6 9 [/SUP], Elizabeth W Petzold[SUP] 9 [/SUP], Juanjie Tang[SUP] 10 [/SUP], Thomas H Oguin 3rd[SUP] 5 6 [/SUP], Gregory D Sempowski[SUP] 5 6 [/SUP], Matthew Gagne[SUP] 11 [/SUP], Daniel C Douek[SUP] 11 [/SUP], Mark A Tomai[SUP] 12 [/SUP], Christopher B Fox[SUP] 13 [/SUP], Robert Seder[SUP] 11 [/SUP], Kevin Wiehe[SUP] 5 6 [/SUP], Drew Weissman[SUP] 14 [/SUP], Norbert Pardi[SUP] 14 [/SUP], Hana Golding[SUP] 10 [/SUP], Surender Khurana[SUP] 10 [/SUP], Priyamvada Acharya[SUP] 5 15 [/SUP], Hanne Andersen[SUP] 16 [/SUP], Mark G Lewis[SUP] 16 [/SUP], Ian N Moore[SUP] 8 [/SUP], David C Montefiori[SUP] 5 15 [/SUP], Ralph S Baric[SUP] 7 [/SUP], Barton F Haynes[SUP] 17 18 19 [/SUP]
Affiliations
Abstract
Betacoronaviruses (betaCoVs) caused the severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) outbreaks, and the SARS-CoV-2 pandemic[SUP]1-4[/SUP]. Vaccines that elicit protective immunity against SARS-CoV-2 and betaCoVs circulating in animals have the potential to prevent future betaCoV pandemics. Here, we show that macaque immunization with a multimeric SARS-CoV-2 receptor binding domain (RBD) nanoparticle adjuvanted with 3M-052/Alum elicited cross-neutralizing antibody (cross-nAb) responses against batCoVs, SARS-CoV-1, SARS-CoV-2, and SARS-CoV-2 variants B.1.1.7, P.1, and B.1.351. Nanoparticle vaccination resulted in a SARS-CoV-2 reciprocal geometric mean neutralization ID50 titer of 47,216, and protection against SARS-CoV-2 in macaque upper and lower respiratory tracts. Importantly, nucleoside-modified mRNA encoding a stabilized transmembrane spike or monomeric RBD also induced SARS-CoV-1 and batCoV cross-nAbs, albeit at lower titers. These results demonstrate current mRNA vaccines may provide some protection from future zoonotic betaCoV outbreaks, and provide a platform for further development of pan-betaCoV vaccines.
. 2021 May 10.
doi: 10.1038/s41586-021-03594-0. Online ahead of print.
Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
Kevin O Saunders[SUP] 1 2 3 4 [/SUP], Esther Lee[SUP] 5 6 [/SUP], Robert Parks[SUP] 5 6 [/SUP], David R Martinez[SUP] 7 [/SUP], Dapeng Li[SUP] 5 6 [/SUP], Haiyan Chen[SUP] 5 6 [/SUP], Robert J Edwards[SUP] 5 6 [/SUP], Sophie Gobeil[SUP] 5 6 [/SUP], Maggie Barr[SUP] 5 6 [/SUP], Katayoun Mansouri[SUP] 5 6 [/SUP], S Munir Alam[SUP] 5 6 [/SUP], Laura L Sutherland[SUP] 5 6 [/SUP], Fangping Cai[SUP] 5 6 [/SUP], Aja M Sanzone[SUP] 5 6 [/SUP], Madison Berry[SUP] 5 6 [/SUP], Kartik Manne[SUP] 5 6 [/SUP], Kevin W Bock[SUP] 8 [/SUP], Mahnaz Minai[SUP] 8 [/SUP], Bianca M Nagata[SUP] 8 [/SUP], Anyway B Kapingidza[SUP] 5 6 [/SUP], Mihai Azoitei[SUP] 5 6 [/SUP], Longping V Tse[SUP] 7 [/SUP], Trevor D Scobey[SUP] 7 [/SUP], Rachel L Spreng[SUP] 5 6 [/SUP], R Wes Rountree[SUP] 5 6 [/SUP], C Todd DeMarco[SUP] 5 6 [/SUP], Thomas N Denny[SUP] 5 6 [/SUP], Christopher W Woods[SUP] 5 6 9 [/SUP], Elizabeth W Petzold[SUP] 9 [/SUP], Juanjie Tang[SUP] 10 [/SUP], Thomas H Oguin 3rd[SUP] 5 6 [/SUP], Gregory D Sempowski[SUP] 5 6 [/SUP], Matthew Gagne[SUP] 11 [/SUP], Daniel C Douek[SUP] 11 [/SUP], Mark A Tomai[SUP] 12 [/SUP], Christopher B Fox[SUP] 13 [/SUP], Robert Seder[SUP] 11 [/SUP], Kevin Wiehe[SUP] 5 6 [/SUP], Drew Weissman[SUP] 14 [/SUP], Norbert Pardi[SUP] 14 [/SUP], Hana Golding[SUP] 10 [/SUP], Surender Khurana[SUP] 10 [/SUP], Priyamvada Acharya[SUP] 5 15 [/SUP], Hanne Andersen[SUP] 16 [/SUP], Mark G Lewis[SUP] 16 [/SUP], Ian N Moore[SUP] 8 [/SUP], David C Montefiori[SUP] 5 15 [/SUP], Ralph S Baric[SUP] 7 [/SUP], Barton F Haynes[SUP] 17 18 19 [/SUP]
Affiliations
- PMID: 33971664
- DOI: 10.1038/s41586-021-03594-0
Abstract
Betacoronaviruses (betaCoVs) caused the severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) outbreaks, and the SARS-CoV-2 pandemic[SUP]1-4[/SUP]. Vaccines that elicit protective immunity against SARS-CoV-2 and betaCoVs circulating in animals have the potential to prevent future betaCoV pandemics. Here, we show that macaque immunization with a multimeric SARS-CoV-2 receptor binding domain (RBD) nanoparticle adjuvanted with 3M-052/Alum elicited cross-neutralizing antibody (cross-nAb) responses against batCoVs, SARS-CoV-1, SARS-CoV-2, and SARS-CoV-2 variants B.1.1.7, P.1, and B.1.351. Nanoparticle vaccination resulted in a SARS-CoV-2 reciprocal geometric mean neutralization ID50 titer of 47,216, and protection against SARS-CoV-2 in macaque upper and lower respiratory tracts. Importantly, nucleoside-modified mRNA encoding a stabilized transmembrane spike or monomeric RBD also induced SARS-CoV-1 and batCoV cross-nAbs, albeit at lower titers. These results demonstrate current mRNA vaccines may provide some protection from future zoonotic betaCoV outbreaks, and provide a platform for further development of pan-betaCoV vaccines.